🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection

RecruitingPhase 4Ages 20 Years - anyAllNational Taiwan University Hospital
NCT04713670 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance. Recent randomized trials showed that 7-day vonoprazan-based triple therapy is superior to 7-day lansoprazole-based triple therapy in Japanese. A recent trial further showed that 7-day vonoprazan-based high dose amoxicillin dual therapy was non-inferior to 7-day vonoprazan-based triple therapy in Japanese. However, whether vonoprazan based dual, triple, and quadruple therapies are superior or non-inferior to lansoprazole based triple or quadruple therapy remains unknown. Objective: The investigators aimed to compare the efficacy and safety of 14-day vonoprazan-based dual therapy, triple therapy, bismuth quadruple therapy, reverse hybrid therapy, and lansoprazole-based bismuth quadruple therapy and triple therap

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with naive H. pylori infection 2. Subjects with over 20 years old Exclusion Criteria: 1. Younger than 20 years old 2. Ever received H. eradication therapy 3. ever received total or subtotal gastrectomy in the past 4. Severe chronic disease, such as end stage renal disease, liver cirrhosis, incurable malignant tumors 5. Women who are pregnant or breastfeeding 6. Those who are not suitable to receive study drugs: such as a history of allergies to study drugs or serious side effects, etc. 7. Patients with chronic hepatitis (AST or ALT \>40 IU/L) 8. Subjects who cannot sign informed consent by themselves
💊

What it tests

  • (A) T-V14
  • (B) T-V7
  • (C) D-V14
  • (D) HD-V14
  • (E) BQ-V14
📍

Where

1 site
National Taiwan University Hospital
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy